Corbus Pharmaceuticals Holdings, Inc. — Form 8-K
Filed November 16, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Corbus presented CANYON-1 Phase 1b data for CRB-913, a CB1 inverse agonist, in 254 obese adults across three doses (20/40/60 mg) over 12 weeks. At 60 mg, CRB-913 achieved statistically significant 5% placebo-adjusted weight loss with dose-dependent reductions in waist circumference and BMI. Treatment discontinuation rate was 8.3%; psychiatric adverse events were infrequent and mild (no serious cases, zero suicidality); gastrointestinal AEs occurred at lower rates than published oral GLP-1 data.
Why this rating
Meaningful clinical validation of obesity asset with competitive efficacy/safety vs. GLP-1s justifies FDA engagement and Phase 2 planning. Relative to $67.8M market cap, successful obesity program could be transformational if development succeeds.
Tradability signal
NO TRADE
No trade: positive news with only -1.1% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.04% over 4 hrs, n=508). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $3.45 ▲ 2.12% | at our read · unknown $3.38 | +10 min · unknown $3.38 ▲ 0.00% | +30 min · unknown $3.32 ▼ 1.66% | +1 hr · unknown $3.34 ▼ 1.07% | +4 hrs · unknown $3.06 ▼ 9.51% |
The stock had already moved -2.07% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.